NCT06581640View on ClinicalTrials.gov

Chimeric Antigen Receptor Modified T Cells Targeting BCMA for the Treatment of Relapsed/Refractory Multiple Myeloma

PHASE2RecruitingINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

September 24, 2024

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2028

Conditions
Multiple MyelomaRelapsed/Refractory
Interventions
BIOLOGICAL

CAR-T treatment

Peripheral blood lymphocyte collection, PBMC separation, BCMA CAR-T cell preparation/storage, lymphodepletion chemotherapy pretreatment for the subject, and BCMA CAR-T cell infusion.

Trial Locations (1)

361000

RECRUITING

The First Affiliated Hospital of Xiamen University, Xiamen

All Listed Sponsors
lead

The First Affiliated Hospital of Xiamen University

OTHER